Legend Biotech
Yahoo Finance • 7 days ago
Legend Biotech (LEGN) Tests Its Valuation After Fresh CARVYKTI Five Year Data
Legend Biotech (LEGN) moved back into focus after releasing five-year follow-up data from its CARTITUDE-2 Cohort A study of CARVYKTI in relapsed or refractory multiple myeloma patients. Despite the encouraging CARTITUDE-2 update, Legend B... Full story
Yahoo Finance • 9 days ago
Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says
Legend Biotech's (LEGN) multiple myeloma therapy Carvykti is facing growing competitive pressure as PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story
Yahoo Finance • 26 days ago
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Legend Biotech USA Inc. Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search process BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporati... Full story
Yahoo Finance • last month
Legend Biotech (LEGN) Heads To Morgan Stanley Conference, Is The 57% Valuation Gap Justified?
Legend Biotech (LEGN) drew fresh investor attention after announcing that interim CEO Alan Bash will speak at the Morgan Stanley Global Healthcare Conference on September 15, 2026. The company plans to highlight its CAR-T focus and commerc... Full story
Yahoo Finance • last month
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know about: It's a healthcare investor. Jo... Full story
Yahoo Finance • 2 months ago
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 2 months ago
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More
Pre-Market Stock Futures: Futures are trading modestly higher as we have arrived at the day everyone on Wall Street has circled on their calendars. The July consumer price index will be released at 8:30 AM EDT, and the producer price inde... Full story
Yahoo Finance • 2 months ago
Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Tuesday, Aug. 11, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Interim Chief Executive Officer - Alan BashChief Financial Officer - Carlos SantosInterim Head of R&D - Yuhong QiuDirector of Investor Relatio... Full story
Yahoo Finance • 2 months ago
Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus
Quick Read LEGN surged 6% as Q2 revenue of $388M beat estimates and adjusted EPS of $0.16 doubled consensus, marking the company's first-ever profitable quarter. CARVYKTI net sales hit $657M, up 50%, with JNJ co-developer Janssen supporti... Full story
Yahoo Finance • 2 months ago
Legend Biotech Q2 Earnings Call Highlights
Key Points Interested in Legend Biotech Corporation Sponsored ADR? Here are five stocks we like better. CARVYKTI sales rose sharply: Worldwide net trade sales increased 50% year over year to approximately $657 million, driven by earlier-l... Full story
Yahoo Finance • 2 months ago
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Amid Stalled US-Iran Talks
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively traded Invesco QQQ Trust (QQQ) was 0.4% higher in Tuesday's premarket activity as stalled US-Iran talks weigh on investors.US stock futures wer... Full story
Yahoo Finance • 2 months ago
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
Legend Biotech USA Inc. BRIDGEWATER N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday,... Full story
Yahoo Finance • 3 months ago
Legend Biotech Announces CEO Transition
Ying Huang, Ph.D., steps down as Chief Executive Officer and member of the Board of Directors; will remain as an advisor through August to support a smooth transitionAlan Bash, current President of the CARVYKTI Business Unit, appointed Int... Full story
Yahoo Finance • 3 months ago
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
Dealmaking is back with a vengeance in the pharmaceutical sector this year. According to a report by PwC, there were more than $65 billion in pharma and life sciences mergers & acquisitions in the first quarter, the best quarter for the se... Full story
Yahoo Finance • 4 months ago
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching
Quick Read Legend Biotech (LEGN) generates $1 billion in CAR-T revenue with J&J already embedded as acquirer, yet trades at roughly half its $58 analyst price target. Aleniglipron posted 16% placebo-adjusted weight loss at 44 weeks, placi... Full story
Yahoo Finance • 4 months ago
Legend Biotech shares slide post-pricing of $226M public offering at $29.35 per unit
Legend Biotech (LEGN [https://seekingalpha.com/symbol/LEGN]) has announced the pricing of an underwritten public offering [https://seekingalpha.com/pr/20555961-legend-biotech-corporation-announces-pricing-of-public-offering] of 7.7M Americ... Full story
Yahoo Finance • 4 months ago
Legend Biotech Prices $226 Million Public Offering; Stock Down
(RTTNews) - Legend Biotech Corporation (LEGN) has priced an underwritten public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 per ADS, raising approximately $226 million in gross proceeds before underwriting discounts... Full story
Yahoo Finance • 4 months ago
Legend Biotech Corporation Announces Pricing of Public Offering
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,... Full story
Yahoo Finance • 4 months ago
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependent in vivo CAR-Texpansion without lympho... Full story
Yahoo Finance • 4 months ago
Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK
The targeted oncology sector is shifting after GSK (GSK [https://seekingalpha.com/symbol/GSK]) decided to buy [https://seekingalpha.com/news/4601644-gsk-to-buy-nuvalent-for-106b] Nuvalent (NUVL [https://seekingalpha.com/symbol/NUVL]) for $... Full story